Novocure

Profile narrative

Novocure is a medical technology company that focuses on the development and delivery of Tumor Treating Fields (TTFields) therapy for patients with solid tumor cancers. Its flagship product, the Optune system, delivers low‑intensity alternating electric fields via transducer arrays placed on the scalp or body to disrupt cancer cell division. The therapy is administered as a portable, wearable device that patients can use in outpatient or home settings. Novocure’s portfolio currently includes indications for glioblastoma, malignant pleural mesothelioma, non‑small cell lung cancer, and several other tumor types that are under investigation or have received regulatory approval in various jurisdictions.

The company is headquartered in Portsmouth, New Hampshire, United States of America, and maintains additional offices in Europe, Asia, and other regions to support global commercialization and clinical development. Novocure operates in numerous countries across North America, Europe, and Asia, providing access to its therapy through a network of specialized treatment centers and partnerships with healthcare providers. Its workforce consists of professionals engaged in research, engineering, regulatory affairs, manufacturing, and commercial functions that span multiple continents.

A distinguishing attribute of Novocure is its pioneering use of TTFields, a non‑invasive physical modality that interferes with the mitotic process of cancer cells without systemic drug exposure. The technology has received clearance or approval from major regulatory bodies such as the U.S. Food and Drug Administration, the European Medicines Agency, and Japan’s Pharmaceuticals and Medical Devices Agency, underscoring its recognized safety and efficacy profile. Novocure’s specialization in combining engineering, oncology, and clinical science has positioned it as a distinct player within the broader oncology market, differentiating it from traditional pharmaceutical and radiation‑based approaches.

Novocure is a publicly traded corporation listed on the NASDAQ stock exchange under the ticker symbol NVCR, with ownership dispersed among institutional and retail investors. The company oversees a set of wholly owned subsidiaries, including Novocure GmbH in Germany and Novocure Ltd in Japan, which handle regional regulatory, manufacturing, and commercial activities. These structural elements enable centralized strategic direction while allowing localized execution in key markets.

Incidents

0 incidents linked to this organisation.